help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MALOUF, M. A.
Right arrow Articles by GLANVILLE, A. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MALOUF, M. A.
Right arrow Articles by GLANVILLE, A. R.

Am. J. Respir. Crit. Care Med., Volume 160, Number 5, November 1999, 1611-1616

The Spectrum of Mycobacterial Infection after Lung Transplantation

MONIQUE A. MALOUF and ALLAN R. GLANVILLE

Heart-Lung Transplant Unit, St. Vincent's Hospital, Sydney, Australia

Despite the success of lung transplantation, infection is one of the leading causes of morbidity and mortality. Mycobacterial infections have been reported rarely, with the majority due to Mycobacterium tuberculosis. Our aim was to assess the incidence, etiology, and clinical outcome of mycobacterial infection after lung transplantation; to do so, we have studied retrospectively all lung and heart- lung transplants performed over a 12-yr period between November 1986 and June 1998 (n = 261). Twenty-three patients (9%) (M:F, 11:12) were diagnosed with mycobacterial infections in 25 sites, including n = 19, pulmonary (M. avium complex [n = 13], M. tuberculosis [n = 2], M. abscessus [n = 2], M. asiaticum [n = 1], and M. kansasii [n = 1]) and n = 6 extrapulmonary (M. haemophilum [n = 5] and M. abscessus [n = 1]) infections. Time to diagnosis from transplantation was 677 ± 735 d (range, 2- 3,086 d). Three episodes of transient colonization with M. avium were not treated; the remaining (22 of 25, 88%) were treated. Initial baseline therapy for nontuberculous mycobacteria included clarithromycin, rifampicin, ciprofloxacin, and/or ethambutol. All cutaneous lesions resolved completely, while clinical and graft function improved in 11 of 16 (69%) and 8 of 16 (50%) of patients treated, respectively. Seventeen of 23 patients (72%) survived at a follow-up of 1,658 ± 759 d (range, 522-3,285 d). Complications, predominantly due to rifampicin, included gastrointestinal intolerance and an increased tendency for rejection. There were no deaths attributable to mycobacterial disease or therapy. We conclude that mycobacterial infection, particularly due to nontuberculous mycobacteria, is relatively common after lung transplantation and may be an unrecognized cause of graft dysfunction. Early treatment of cutaneous lesions is associated with excellent control; however, graft dysfunction may be permanent. Although drug toxicity and interactions with immunosuppressive agents were not infrequent, the majority of these infections can be managed successfully. Malouf MA and Glanville AR. The spectrum of mycobacterial infection after lung transplantation.




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
A. R. Glanville, C. L. Aboyoun, A. Havryk, M. Plit, S. Rainer, and M. A. Malouf
Severity of Lymphocytic Bronchiolitis Predicts Long-Term Outcome after Lung Transplantation
Am. J. Respir. Crit. Care Med., May 1, 2008; 177(9): 1033 - 1040.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
B. E. Jonsson, M. Gilljam, A. Lindblad, M. Ridell, A. E. Wold, and C. Welinder-Olsson
Molecular Epidemiology of Mycobacterium abscessus, with Focus on Cystic Fibrosis
J. Clin. Microbiol., May 1, 2007; 45(5): 1497 - 1504.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. Hadjiliadis
Special Considerations for Patients With Cystic Fibrosis Undergoing Lung Transplantation
Chest, April 1, 2007; 131(4): 1224 - 1231.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. E. Griffith, T. Aksamit, B. A. Brown-Elliott, A. Catanzaro, C. Daley, F. Gordin, S. M. Holland, R. Horsburgh, G. Huitt, M. F. Iademarco, et al.
An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases
Am. J. Respir. Crit. Care Med., February 15, 2007; 175(4): 367 - 416.
[Full Text] [PDF]

Home page
 J Intensive Care MedHome page
J. L. Taylor and S. M. Palmer
Critical Care Perspective on Immunotherapy in Lung Transplantation
J Intensive Care Med, December 1, 2006; 21(6): 327 - 344.
[Abstract] [PDF]

Home page
 ChestHome page
S. K. Field and R. L. Cowie
Lung Disease Due to the More Common Nontuberculous Mycobacteria
Chest, June 1, 2006; 129(6): 1653 - 1672.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
W Chalermskulrat, N Sood, I P Neuringer, T M Hecker, L Chang, M P Rivera, L J Paradowski, and R M Aris
Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation
Thorax, June 1, 2006; 61(6): 507 - 513.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. M. Kotloff, V. N. Ahya, and S. W. Crawford
Pulmonary Complications of Solid Organ and Hematopoietic Stem Cell Transplantation
Am. J. Respir. Crit. Care Med., July 1, 2004; 170(1): 22 - 48.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
D Shitrit, D Bendayan, M Saute, and M R Kramer
Multidrug resistant tuberculosis following lung transplantation: treatment with pulmonary resection
Thorax, January 1, 2004; 59(1): 79 - 80.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1999 American Thoracic Society